Inmunidad de las Mucosas y Alergia: de la Inmunopatología a la Terapia.
![Foto de Inmunidad de las Mucosas y Alergia: de la Inmunopatología a la Terapia.](/img/uploaded/21C42DF6CDA0E8472C44DA6D4C40ABE3.png)
![Foto de Hospital Universitari de Bellvitge](/img/noimage_org.png)
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (29)
2024
-
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Pharmaceutics, Vol. 16, Núm. 5
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Current management of bowel failure due to Crohn's disease in Spain: Results of a GETECCU survey
Gastroenterologia y Hepatologia, Vol. 46, Núm. 6, pp. 439-445
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
-
Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)
Nature
-
Genetic Architecture of Ischaemic Strokes after COVID-19 Shows Similarities with Large Vessel Strokes
International Journal of Molecular Sciences, Vol. 24, Núm. 17
2022
2021
-
European registry on helicobacter pylori management: Effectiveness of first and second-line treatment in Spain
Antibiotics, Vol. 10, Núm. 1, pp. 1-15
-
Mapping the human genetic architecture of COVID-19
Nature, Vol. 600, Núm. 7889, pp. 472-477
-
Persistent Villous Atrophy in De Novo Adult Patients With Celiac Disease and Strict Control of Gluten-Free Diet Adherence: A Multicenter Prospective Study (CADER Study)
The American journal of gastroenterology, Vol. 116, Núm. 5, pp. 1036-1043
2020
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616
-
Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)
Helicobacter, Vol. 25, Núm. 3
2019
-
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results from the ENEIDA Registry
Inflammatory Bowel Diseases, Vol. 25, Núm. 11, pp. 1862-1870
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
-
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study
Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500
-
Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients
Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854
2018
-
Human intestinal pro-inflammatory CD11chighCCR2+CX3CR1+ macrophages, but not their tolerogenic CD11c-CCR2-CX3CR1- counterparts, are expanded in inflammatory bowel disease article
Mucosal Immunology, Vol. 11, Núm. 4, pp. 1114-1126
-
Increased prevalence of pathogenic bacteria in the gut microbiota of infants at risk of developing celiac disease: The PROFICEL study
Gut Microbes, Vol. 9, Núm. 6, pp. 551-558
-
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients
Gastroenterologia y Hepatologia
2017
-
Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment
Digestive and Liver Disease, Vol. 49, Núm. 9, pp. 973-977